Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-0500

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma ; volume:14 ; number:1 ; day:28 ; month:5 ; year:2021 ; pages:1-6 ; date:12.2021
BMC Research Notes / Biomed Central ; 14, Heft 1 (28.5.2021), 1-6, 12.2021

Creator: Saputro, Ridwan Dwi
Rinonce, Hanggoro Tri
Iramawasita, Yayuk
Ridho, Muhammad Rasyid
Pudjohartono, Maria Fransiska
Anwar, Sumadi Lukman
Setiaji, Kunto
Aryandono, Teguh

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13104-021-05623-7

URN: urn:nbn:de:101:1-2021092419383405487699

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Saputro, Ridwan Dwi
Rinonce, Hanggoro Tri
Iramawasita, Yayuk
Ridho, Muhammad Rasyid
Pudjohartono, Maria Fransiska
Anwar, Sumadi Lukman
Setiaji, Kunto
Aryandono, Teguh
SpringerLink (Online service)

Other Objects (12)

MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

The Regulation of PD-L1 Secretion in Extracellular Vesicles by Melanoma Cells

RSK1 activation promotes invasion in nodular melanoma

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

The Regulation of PD-L1 Secretion in Extracellular Vesicles by Melanoma Cells

RSK1 activation promotes invasion in nodular melanoma

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

The Regulation of PD-L1 Secretion in Extracellular Vesicles by Melanoma Cells

RSK1 activation promotes invasion in nodular melanoma

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

The Regulation of PD-L1 Secretion in Extracellular Vesicles by Melanoma Cells

RSK1 activation promotes invasion in nodular melanoma

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

The Regulation of PD-L1 Secretion in Extracellular Vesicles by Melanoma Cells

RSK1 activation promotes invasion in nodular melanoma

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

The Regulation of PD-L1 Secretion in Extracellular Vesicles by Melanoma Cells

RSK1 activation promotes invasion in nodular melanoma

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

Related objects

Reset password